Nuwellis Inc Stock Price, News & Analysis

Nuwellis (Nasdaq: NUWE) has achieved a significant milestone with the first successful treatment of patients using its Aquadex SmartFlow® ultrafiltration therapy in a hospital-based outpatient setting. This advancement follows the recent CMS decision to increase outpatient reimbursement from $413 to $1,639 per treatment day.

The treatment, performed at a leading healthcare institution in the southeastern United States, demonstrates Nuwellis's progress in expanding access to fluid management therapy. The outpatient model allows for treatment using existing venous access and care teams without requiring hospitalization, potentially reducing hospital readmissions while maintaining the same trusted clinical protocols used in inpatient settings.

Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management, announced that stockholders approved all proposals at their Special Meeting. The key approvals include: warrant exercise authorization for the June 2025 financing, an increase in authorized common stock from 100 million to 200 million shares, and authorization for a potential reverse stock split at a ratio between 1-for-5 and 1-for-70.

The reverse split authorization aims to maintain Nasdaq listing compliance, while the other measures are designed to enhance financial flexibility and support strategic growth initiatives.

Nuwellis (NUWE) announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Erb presented at the event, sharing insights about his leadership journey, commitment to the company, and passion for Nuwellis' development programs.

The presentation is now accessible to investors through the Virtual Investor platform and Nuwellis' corporate website in the Investors section.

Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid management solutions, has successfully regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company received formal confirmation from Nasdaq on July 22, 2025, resolving their previously disclosed bid price deficiency.

As a result, the scheduled hearing with the Nasdaq Hearings Panel for August 12, 2025, has been cancelled, and Nuwellis' common stock will continue trading on the Nasdaq Capital Market under the ticker "NUWE".

Nuwellis (Nasdaq: NUWE), a medical technology company specializing in fluid overload treatments, has scheduled its second quarter 2025 financial results announcement for August 12, 2025. The company will host a conference call and webcast at 9:00 AM ET to discuss the results and provide business updates.

Investors can access the live webcast through the company's investor relations website at ir.nuwellis.com, or join the conference call by dialing 1-800-245-3047 (U.S.) or 1-203-518-9765 (international) using conference ID: NUWEQ2.

Nuwellis (NASDAQ:NUWE) announced the termination of its REVERSE-HF clinical trial, which was evaluating ultrafiltration versus IV loop diuretic therapy for fluid management in hospitalized heart failure patients. The company will redirect its focus toward outpatient heart failure care, pediatric, and critical care markets.

The trial, which began in 2022, had enrolled 167 patients before termination. This strategic decision is expected to save $4.0 million over 2.5 years. The company plans to analyze existing data for potential clinical publications. Importantly, the termination was not due to device performance or safety concerns, and the Nuwellis SmartFlow® remains FDA-cleared for fluid overload treatment.

Nuwellis (Nasdaq: NUWE) has been granted U.S. Patent No. 12,357,734 for its innovative blood filtering technology. The patent, titled "Extracorporeal Blood Filtering Machine and Methods," focuses on improving fluid balance calculation accuracy in continuous renal replacement therapy (CRRT) systems.

The patented technology addresses a critical issue in CRRT systems by accounting for varying fluid densities, moving beyond the standard assumption of 1 g/mL. This advancement enables more precise volumetric flow tracking, potentially reducing clinically relevant fluid balance errors.

The patent strengthens Nuwellis' intellectual property portfolio and reinforces its position in the fluid management therapy sector.

Nuwellis (Nasdaq: NUWE) has appointed John Erb as its permanent Chief Executive Officer, effective June 27, 2025. Erb, who has been serving as interim CEO since February 2025, previously held the CEO position from 2015 to 2020. This appointment follows his successful interim leadership period where he demonstrated ability to bring stability and renewed momentum to the medical technology company.

The Board's decision reflects their confidence in Erb's leadership capabilities and his deep understanding of Nuwellis's mission in advancing fluid management solutions. Under his guidance, the company aims to focus on strategic clarity, operational discipline, and sustainable growth.

Nuwellis (NUWE) has completed a $5.0 million public offering, including the full exercise of the overallotment option. The offering consisted of 2,580,667 common shares and 14,085,998 pre-funded warrants, along with accompanying Series A and Series B Warrants. The common stock and warrants were priced at $0.30 per share, while pre-funded warrants were offered at $0.2999. Series A and B Warrants have a $0.30 exercise price and a 5-year exercise period following stockholder approval. Series A Warrants include a one-time price reset provision tied to potential reverse stock splits, while Series B Warrants feature a zero-cash exercise option. Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering.